Dashboard
Manage Tickers

CTLT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

william-blair-reiterates-market-perform-on-catalent
William Blair Reiterates Market Perform on...
09/03/2024 14:54:20

William Blair analyst Max Smock reiterates Catalent (NYSE:CTLT) with a Market Perform.

catalent-q4-2024-adj-eps-065-beats-047-estimate-sales-1301b-beat-1224b-estimate
Catalent Q4 2024 Adj. EPS $0.65 Beats $0.4...
08/29/2024 11:45:10

Core News & Articles
Lilly Executive Says Concord Manufacturing...
08/08/2024 14:52:15

Conference Call

Core News & Articles
Novo Nordisk CFO Said In Active Dialogue W...
08/07/2024 11:41:07

catalent-completes-25m-upgrade-to-schorndorf-site-featuring-expanded-storage-and-new-fastchain-area
Catalent Completes $25M Upgrade To Schornd...
07/16/2024 06:29:42

The expansion increases the site's footprint by 32,000 square feet (3,000 square meters), adding storage and handling of cl...

rbc-capital-reiterates-sector-perform-on-catalent-maintains-635-price-target
RBC Capital Reiterates Sector Perform on C...
07/11/2024 15:00:20

RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.

barclays-maintains-equal-weight-on-catalent-raises-price-target-to-63
Barclays Maintains Equal-Weight on Catalen...
06/28/2024 15:43:01

Barclays analyst Luke Sergott maintains Catalent (NYSE:CTLT) with a Equal-Weight and raises the price target from $47 to $63.

sareptas-expanded-approval-unlikely-to-influence-novo-holdings-acquisition-of-catalent-but-provides-investor-protection-amid-uncertainty
Sarepta's Expanded Approval Unlikely To In...
06/21/2024 17:52:17

Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/rew...

catalent-stockholders-approve-acquisition-by-novo-holdings-for-6350-per-share-in-cash
Catalent Stockholders Approve Acquisition ...
05/29/2024 13:08:31

hedge-funds-tweak-portfolios-in-q1-marvell-td-synnex-aes-get-more-love-as-focus-shifts-to-ai
Hedge Funds Tweak Portfolios In Q1: Marvel...
05/24/2024 16:19:57

Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors a...

catalent-q3-eps-006-misses-021-estimate-sales-107b-miss-112b-estimate
Catalent Q3 EPS $(0.06) Misses $0.21 Estim...
05/08/2024 22:25:21

Catalent (NYSE:CTLT) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.21 by 128...

siren-biotechnology-and-catalent-partner-to-manufacture-aav-gene-therapies-for-cancer
Siren Biotechnology And Catalent Partner T...
05/08/2024 15:05:04

demand-soars-for-novo-nordisks-weight-loss-drug-wegovy-despite-supply-constraints-and-eli-lilly-competition
Demand Soars For Novo Nordisk's Weight-Los...
05/02/2024 09:48:44

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply con...

novo-nordisks-dominance-in-obesity--diabetes-drug-market-backed-by-strong-pipeline-analyst-gives-outperform-rating
Novo Nordisk's Dominance In Obesity & Diab...
04/12/2024 17:22:39

BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts fo...

beyond-the-numbers-6-analysts-discuss-catalent-stock
Beyond The Numbers: 6 Analysts Discuss Cat...
04/04/2024 15:01:07

stephens--co-reiterates-equal-weight-on-catalent-maintains-635-price-target
Stephens & Co. Reiterates Equal-Weight on ...
04/04/2024 14:26:35

Stephens & Co. analyst Jacob Johnson reiterates Catalent (NYSE:CTLT) with a Equal-Weight and maintains $63.5 price target.

invenra-to-collaborate-with-catalent-to-co-discover-novel-bispecific-adcs
Invenra To Collaborate With Catalent To Co...
04/02/2024 17:59:04

https://www.businesswire.com/news/home/20240402320363/en/

novo-nordisk-sets-timeframe-for-its-next-gen-experimental-obesity-drug
Novo Nordisk Sets Timeframe For Its Next-G...
03/08/2024 16:12:01

"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect ...

Core News & Articles
Novo Nordisk CFO Says If Catalent Deal Doe...
03/07/2024 16:01:02

Core News & Articles
Novo Nordisk CFO Says If Catalent Deal Doe...
03/07/2024 15:47:42

- Conf Call

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION